Ronnie-Mahofski

RQM+ Appoints Mahofski as Head of Mergers and Acquisitions

By MedTech Intelligence Staff
Ronnie-Mahofski

Mahofski will be responsible for identifying and pursuing acquisition opportunities that complement RQM+’s core regulatory services and provide a comprehensive range of fully integrated outsourced solutions to help get MedTech products to market faster and ensure ongoing regulatory compliance.

Ronnie Mahofski is the new head of mergers and acquisitions (M&A) at RQM+, a global provider of MedTech regulatory and quality experts.

Mahofski has more than 20 years of experience in the MedTech industry and has held various positions at RQM+, including overseeing M&A integration and business development. He previously served as VP of engineering for Circadiance and as a project manager for MEDRAD. In his new role at RQM+, Mahofski is responsible for identifying and pursuing acquisition opportunities that complement its core regulatory services and provide a comprehensive range of fully integrated outsourced solutions to help get MedTech products to market faster and ensure ongoing regulatory compliance.

“We’re rapidly becoming the organization that will help medical device companies connect the dots from concept through market deployment and maintenance, expediting patient access to life-improving technologies,” said Mahofski. “In the coming years, we will continue to expand our offerings to support MedTech customers throughout the product lifecycle. They recognize the significant time and cost savings they can achieve by running many key processes in parallel through one trusted partner.”

Mahofski started his career as a nuclear submarine junior officer on the USS Tennessee. He earned his bachelor’s degree in systems engineering at the U.S. Naval Academy and his Master of Business Administration, with a concentration in finance, from Waynesburg University.

 

Related Articles

  • RQM plus logo

    Jordi labs and its team of Ph.D. analytical chemists developed a proprietary, multi-detector approach to ensure that all extractables are accurately characterized to comply with global materials testing regulatory requirements.

  • FDA CERSI logo

    The CERSI program was established to foster robust and innovative approaches to advance regulatory science through collaborative interactions with FDA scientific experts.

  • Pixabay Globe

    The increase in global regulatory demands for medical devices has presented new challenges for regulatory affairs and intelligence teams. On May 16-17, The MedTech Regulatory Intelligence Summit will bring together regulatory professionals, device developers and regulators to look at current…

  • MedTech Regulatory Intelligence Summit

    On May 16-17, device developers, regulatory affairs and regulatory intelligence professionals will come together in Washington, DC, for two days of education, discussion and networking to share strategies and best practices on navigating current and on the horizon regulatory requirements.

About The Author

MedTech Intelligence